Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar


The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.

After SharkTank’s Mark Cuban teased that his online pharmacy (Mark Cuban Cost Plus Drug Company) would eventually add biosimilars to its list of low-cost drugs in February, Coherus Biosciences announced that it will join forces with Cuban’s company to make an biosimilar referencing Humira (adalimumab) available to patients at an affordable price.

box and autoinjector for Yusimry

Yusimry will be offered with an autoinjector presentation.

The biosimilar, Yusimry (adalimumab-aqvh), was approved in December 2021 and is projected to launch in July 2023. It is 1 of 9 FDA-approved adalimumab biosimilars and is a low-concentration, citrate-free product. It is a tumor necrosis factor inhibitor indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

“We believe there is a large, unmet need for improved access and affordability for patients in the U.S. health care system that together Cost Plus Drugs and Yusimry can help address…. This agreement is part of our biosimilar strategy to leverage our excellence in manufacturing and supply chain management to deliver safe and effective biosimilars with ensured, reliable supply,” commented Denny Lanfear, CEO of Coherus.

Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) will offer Yusimry to customers at $569.27 plus dispensing and shipping fees beginning in July 2023. The biosimilar will be available with an autoinjector presentation featuring a 29-gauge needle.

Cost Plus Drugs logo

Yusimry will also be included in the Team Cuban Card prescription benefit program through participating pharmacies. The Team Cuban Card allows for patients to obtain their prescriptions from a local independent pharmacy at the same price they would get at Cost Plus Drugs. The program also provides the independent pharmacy community with reasonable dispensing fees and a transparent pricing structure.

“Cost Plus Drugs is saving patients hundreds and thousands of dollars a month by pricing our medications fairly at our cost plus 15%.... Adding Yusimry, a biosimilar of Humira, to Cost Plus Drugs will extend these savings to biologics. This is just our first step in making biologics affordable for patients,” said Cuban.

Cuban is best known as an investor on ABC’s Shark Tank as well as the owner of the Dallas Mavericks. He started his career as an entrepreneur by creating MicroSolutions, a computer consulting service, which he sold in 1990 for $6 million. He announced the launch of his online pharmacy in January 2022.

Cuban spoke at the Association for Accessible Medicines (Access 2023) as part of a fireside chat in February 2023, where he talked about why he chose to develop an online pharmacy that specializes in low-cost medicines and acts as a disruptor to big pharmaceutical wholesale manufacturers. During the talk, he said that while Cost Plus Drugs only carried generic medications at the time, he wasn’t going to rule out adding biosimilar options down the road.

“Humira is the top-selling medicine of all time, but for those without insurance or who are underinsured, this therapy and other biologic medicines have been out of reach due to price,”. said Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company, in a statement from Coherus.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.